Skip to main content

Advertisement

Articles

17 result(s) for 'yoshiya tanaka' within Arthritis Research & Therapy

Page 1 of 1

  1. Content type: Research article

    Biologic disease-modifying antirheumatic drugs (bDMARDs) are important options for managing rheumatoid arthritis (RA). Once patients achieve disease control, clinicians may consider dose reduction or withdrawa...

    Authors: Yoshiya Tanaka, Josef S. Smolen, Heather Jones, Annette Szumski, Lisa Marshall and Paul Emery

    Citation: Arthritis Research & Therapy 2019 21:164

    Published on:

  2. Content type: Research article

    Tumor necrosis factor (TNF) inhibitors (TNF-i) are effective in the treatment of entero-Behcet’s disease (BD). However, there is no objective tool for assessment of disease activity in entero-BD; therefore, it...

    Authors: Ippei Miyagawa, Kazuhisa Nakano, Shigeru Iwata, Shingo Nakayamada, Kazuyoshi Saito, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Akio Kawabe, Yusuke Miyazaki and Yoshiya Tanaka

    Citation: Arthritis Research & Therapy 2019 21:151

    Published on:

  3. Content type: Correction

    Following publication of the original article [1], the authors reported an error in Table 2.

    Authors: Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham and Hideto Kameda

    Citation: Arthritis Research & Therapy 2019 21:99

    Published on:

    The original article was published in Arthritis Research & Therapy 2019 21:79

  4. Content type: Research

    Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor α. This bridging study assessed the effic...

    Authors: Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham and Hideto Kameda

    Citation: Arthritis Research & Therapy 2019 21:79

    Published on:

    The Correction to this article has been published in Arthritis Research & Therapy 2019 21:99

  5. Content type: Research article

    Dermatomyositis (DM) with rapidly progressive interstitial lung disease (DM RP-ILD) is a life-threatening condition. Serum cytokine levels are potentially suitable biomarkers for DM RP-ILD. However, the relati...

    Authors: Yuichi Ishikawa, Shigeru Iwata, Kentaro Hanami, Aya Nawata, Mingzeng Zhang, Kaoru Yamagata, Shintaro Hirata, Kei Sakata, Yasuyuki Todoroki, Kazuhisa Nakano, Shingo Nakayamada, Minoru Satoh and Yoshiya Tanaka

    Citation: Arthritis Research & Therapy 2018 20:240

    Published on:

  6. Content type: Research article

    Following the onset of rheumatoid arthritis (RA), patients experience a functional decline caused by various joint symptoms which affects their activities of daily living and can lead to reduced work productiv...

    Authors: Yoshiya Tanaka, Hideto Kameda, Kazuyoshi Saito, Yuko Kaneko, Eiichi Tanaka, Shinsuke Yasuda, Naoto Tamura, Keishi Fujio, Takao Fujii, Toshihisa Kojima, Tatsuhiko Anzai, Chikuma Hamada, Yoshihisa Fujino, Shinya Matsuda and Hitoshi Kohsaka

    Citation: Arthritis Research & Therapy 2018 20:151

    Published on:

  7. Content type: Research article

    Sirukumab, a high-affinity human monoclonal antibody that selectively binds to interleukin-6, has demonstrated efficacy in the treatment of rheumatoid arthritis (RA) in global phase 1 and phase 2 studies. The ...

    Authors: Tsutomu Takeuchi, Hisashi Yamanaka, Masayoshi Harigai, Ryo Tamamura, Yuichi Kato, Yoshifumi Ukyo, Toshikazu Nakano, Benjamin Hsu and Yoshiya Tanaka

    Citation: Arthritis Research & Therapy 2018 20:42

    Published on:

  8. Content type: Research article

    This study was conducted to evaluate the feasibility of long-term adalimumab (ADA) discontinuation after achievement of low disease activity (LDA) in Japanese patients with early rheumatoid arthritis (RA) and ...

    Authors: Yoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, Nobuyuki Miyasaka, Katsuyoshi Kawana, Junko Kimura, Naoki Agata and Tsutomu Takeuchi

    Citation: Arthritis Research & Therapy 2017 19:56

    Published on:

  9. Content type: Research article

    Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, tofacitinib safety and efficacy data from a long-term extension study in Japanese patients are presented.

    Authors: Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, Naonobu Sugiyama, Hirotoshi Yuasa, Shigeyuki Toyoizumi, Yosuke Morishima, Tomohiro Hirose and Samuel Zwillich

    Citation: Arthritis Research & Therapy 2016 18:34

    Published on:

  10. Content type: Research article

    Treat-to-target strategies to achieve low disease activity or clinical remission are key in the treatment of rheumatoid arthritis (RA). 14-3-3η is a joint-derived biomarker that is expressed at significantly h...

    Authors: Shintaro Hirata, Anthony Marotta, Yuan Gui, Kentaro Hanami and Yoshiya Tanaka

    Citation: Arthritis Research & Therapy 2015 17:280

    Published on:

  11. Content type: Research article

    The objective of this study was to directly compare the safety of tocilizumab (TCZ) and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice.

    Authors: Ryoko Sakai, Soo-Kyung Cho, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Michi Tanaka, Ryuji Koike, Yoshiya Tanaka, Kazuyoshi Saito, Shintaro Hirata, Koichi Amano, Hayato Nagasawa, Takayuki Sumida, Taichi Hayashi, Takahiko Sugihara, Hiroaki Dobashi…

    Citation: Arthritis Research & Therapy 2015 17:74

    Published on:

  12. Content type: Research article

    Pneumocystis pneumonia (PCP) is one of the most prevalent opportunistic infections in patients undergoing immunosuppressive therapy. In this article, we discuss risk factors for PCP development in patients with r...

    Authors: Takayuki Katsuyama, Kazuyoshi Saito, Satoshi Kubo, Masao Nawata and Yoshiya Tanaka

    Citation: Arthritis Research & Therapy 2014 16:R43

    Published on:

  13. Content type: Research article

    Evidences of biologics-free disease control after discontinuing adalimumab (ADA) in rheumatoid arthritis (RA) patients in clinical practice have not been sufficiently investigated. Purpose of this study is to ...

    Authors: Shintaro Hirata, Kazuyoshi Saito, Satoshi Kubo, Shunsuke Fukuyo, Yasushi Mizuno, Shigeru Iwata, Masao Nawata, Norifumi Sawamukai, Kazuhisa Nakano, Kunihiro Yamaoka and Yoshiya Tanaka

    Citation: Arthritis Research & Therapy 2013 15:R135

    Published on:

  14. Content type: Research article

    Anti-TNF therapies have revolutionized the treatment of rheumatoid arthritis (RA), a common systemic autoimmune disease involving destruction of the synovial joints. However, in the practice of rheumatology ap...

    Authors: Wolfgang Hueber, Beren H Tomooka, Franak Batliwalla, Wentian Li, Paul A Monach, Robert J Tibshirani, Ronald F Van Vollenhoven, Jon Lampa, Kazuyoshi Saito, Yoshiya Tanaka, Mark C Genovese, Lars Klareskog, Peter K Gregersen and William H Robinson

    Citation: Arthritis Research & Therapy 2009 11:R76

    Published on:

  15. Content type: Research article

    Rho is a major small GTP-binding protein that is involved in the regulation of various cell functions, including proliferation and cell migration, through activation of multiple signaling molecules in various ...

    Authors: Shingo Nakayamada, Hitoshi Kurose, Kazuyoshi Saito, Akira Mogami and Yoshiya Tanaka

    Citation: Arthritis Research & Therapy 2005 7:R476

    Published on:

Annual Journal Metrics

Advertisement